PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 15:24:00·⟳ 抓取 15:24:32 +32s·⚡ 决策 08-31 15:26:19 +1m47s·57.1 天前
SBS律所提醒Capricor证券欺诈集体诉讼首席原告期限
不做:当前信号是证券诉讼招募稿,核心负面事实来自此前FDA AdCom负面投票、BLA延期和公司已披露风险;没有新增FDA裁决、法院进展、赔偿金额或经营现金流损害。
📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES,…
不做 Capricor Therapeutics, Inc.(CAPR.US)
不做:证券诉讼招募稿缺少新增FDA、法院或赔偿金额事实,核心负面已在7月底AdCom投票和8月PDUFA延期中公开,盘前追空edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
CAPR的Deramiocel监管风险已经在7月30日公司公告和8月24日PDUFA延期中公开,本次PRNewswire稿只是律所围绕既有股价损失和既有监管争议招募投资者参与集体诉讼。事件方向偏负面,但新增信息主要是诉讼程序提醒,无法量化新增损害,也不足以支撑盘前追空;因此回避。
消息传播链
- 律所发布CAPR证券欺诈集体诉讼首席原告期限提醒;这是本次具体催化的可见来源。
关键理由
- 本条负面核心不是新的FDA审评事实,而是律所对既有证券诉讼的首席原告提醒。
- 公司7月30日已披露FDA咨询委员会以3票赞成、9票反对认为证据不支持DMD心肌病适应症有效性,主要监管风险已先行公开。
- 8月24日公司已披露Deramiocel BLA的PDUFA日期延至2026-11-22,说明审评节奏变化也并非本条新增。
主要风险
- 若后续出现法院受理重大赔偿进展、SEC调查或FDA正式拒批,CAPR.US仍可能触发新的强空事件。
- 未使用实时stock_quote报价,因本结论不下ENTER单,价格不作为入场依据。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
公司已披露BLA延期审评且FDA继续审查补充数据,说明本条诉讼稿没有新增拒批或监管终局结果。
检索:Capricor Deramiocel FDA PDUFA extension August 24 2026 company announcement 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
核心负面AdCom投票已在一个月前由公司公告,当前诉讼稿更多是对既有股价损失的法律追索。
检索:Capricor FDA advisory committee Deramiocel July 30 2026 vote 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论;本次回避的主因是无新增基本面事实而非先例缺失。
方向:未使用历史先例定方向;律所集体诉讼提醒通常属于衍生性程序噪音,本次已可由一手背景事实判断无新增交易增量。
涨幅量级:没有足够高相似、同市场、同相位的先例可用来校准短线幅度。
形态:未观察到可迁移的高质量先例样本。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,837 字
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。